Document is current
Any future updates will be listed below
-
Authors
Velligan, Dawn
Salinas, Gregory D.
Belcher, Emily
Franzenburg, Kelli R.
Suett, Mark
Thompson, Stephen
Hansen, Rolf T. III
-
Funding
Funding for this research was provided by:
Teva Branded Pharmaceutical Products R&D, Inc.
- License Information
-
More Information
Article History
Received: 2 February 2024
Accepted: 31 January 2025
First Online: 11 March 2025
Declarations
:
: This study was exempted from institutional review board oversight by Western Institutional Review Board (Puyallup, WA) under the Common Rule 45 CFR ยงย 46.104(d)(2) (research only included interactions involving survey procedures, and there were adequate provisions to maintain participant privacy and confidentiality). Respondents provided informed consent prior to completing the survey.
: Not applicable.
: Dawn Velligan has received medical writing support from CE Outcomes; consulting fees from Alkermes, Janssen, and Otsuka; travel support from Alkermes and Otsuka; and advisory board support from Janssen, Merck, and Otsuka. Gregory D Salinas and Emily Belcher are employees of CE Outcomes, LLC, which has received payments from Teva Pharmaceuticals in relation to this study. Kelli R Franzenburg, Mark Suett, Stephen Thompson, and Rolf T Hansen III are employees and shareholders of Teva Pharmaceuticals.
